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The role of rare variants in complex traits remains uncharted. Here, we conduct deep whole
genome sequencing of 1457 individuals from an isolated population, and test for rare variant
burdens across six cardiometabolic traits. We identify a role for rare regulatory variation,
which has hitherto been missed. We ﬁnd evidence of rare variant burdens that are inde-
pendent of established common variant signals (ADIPOQ and adiponectin, P= 4.2 × 10−8;
APOC3 and triglyceride levels, P= 1.5 × 10−26), and identify replicating evidence for a burden
associated with triglyceride levels in FAM189B (P= 2.2 × 10−8), indicating a role for this gene
in lipid metabolism.
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Genome-wide association studies have gleaned substantialinsights into the genetic architecture of complex traits.The contribution of common-frequency variants to
complex traits has been well-documented, and progress in
understanding the role of low frequency variation has also gained
considerable traction. However, the role of rare variants in the
genetic architecture of medically-relevant complex traits remains
less well-understood, and the allelic architecture of complex trait
association signals has not yet been fully resolved. Rare variant
association studies have so far mainly focussed on exonic
regions1, and in whole-genome sequencing studies the optimal
analytical approach for rare regulatory variants remains an open
question2. Population-scale deep whole genome sequencing can
capture genetic variation across the entire allele frequency spec-
trum traversing the coding and non-coding genome. In addition,
population isolates offer increased power gains in detecting
associations involving rare and low-frequency variants3.
Here, to improve our understanding of the role of rare variants,
we perform cohort-wide deep whole genome sequencing of 1457
individuals from a deeply-phenotyped, isolated population
from Crete, Greece (the HELIC-MANOLIS cohort4–6) at an
average depth of 22.5× (Supplementary Fig. 1), capturing 98% of
true single nucleotide variants (SNVs) (Methods and Supple-
mentary Fig. 2). The population genetics characteristics of
HELIC-MANOLIS have been studied, and indicate an effective
population size of Ne= 6242 and an approximate time of diver-
gence of 1100 years from the general Greek population4,7. We
address open questions on whole genome sequencing study
design, analysis and interpretation, and identify burdens of cod-
ing and regulatory rare variants associated with cardiometabolic
traits.
Results
Effect of sequencing depth. Comparing whole genome sequen-
cing at various depths ranging from 15× to 30× (Methods), we
ﬁnd that 96.4% of singletons, 97.9% of doubletons and 97.6% of
variants called using 30× sequencing are recapitulated at 22.5x
depth. Genotype accuracy (as measured by r2) is 99.7% for 22.5×
depth and 98.5% for 15× depth, suggesting that increases between
15× and 30× translate into marginal improvements in both call
rate and quality of very rare SNVs (Fig. 1, Supplementary Fig. 3
and Methods). We ﬁnd that false discovery rates and genotype
accuracy are substantially more dependent on sequencing depth
for INDELs than for SNVs (Fig. 1).
Landscape of sequence variation. Following quality control
(QC), we call 24,163,896 non-monomorphic SNVs and INDELs,
97.9% of which are biallelic. 14,281,180 (60.31%) of the biallelic
SNVs are rare (minor allele frequency [MAF] < 0.01); 3,103,273
(13.1%) are low-frequency (MAF 0.01–0.05); and 6,292,726
(26.57%) are common (MAF > 0.05). We call 8,294 non-
monomorphic variants annotated as loss-of-function (LoF) with
low-conﬁdence (LC)8, and 438 variants annotated as LoF with
high-conﬁdence (HC) (Supplementary Fig. 4). On average, each
individual carries 405 (standard deviation σ= 19) LC LoF variants
and 31 (σ= 6) HC LoF variants, compared to 149 LoF variants per
sample in a whole genome sequencing study of 2636 Icelanders9.
0.6 and 1% of HC and LC LoF carrier genotypes are homozygous,
respectively. INDELs are signiﬁcantly more frequent among LoF
variants, with 53.2 and 76% in the low-conﬁdence and high-
conﬁdence sets, respectively, compared to 13.5% genome-wide.
We observe an enrichment of rare variants among the coding and
splice variant categories in MANOLIS (one-sided exact binomial
P= 9.5 × 10−16), and we recapitulate this in an independent
dataset of 3724 individuals with whole genome sequencing from
the UK-based INTERVAL cohort10(Fig. 2). We also observe a
lower rate of singletons compared to the general Greek population
and the INTERVAL cohort (P ≈ 10−167 and P < 10−200, respec-
tively, one-sided empirical P-value) (Methods and Supplementary
Fig. 5), in keeping with the isolated nature of this Cretan popu-
lation. Among the 5,102,175 novel biallelic variants (not present in
gnomAD11 or Ensembl release 8412), 4,394,678 are SNVs, and the
majority are rare (Supplementary Fig. 6).
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Fig. 1 Variant discovery and quality in WGS data from 100 samples. a variant discovery rate in 22.5×; b allelic r2 for SNVs and INDELs in both 15× and 22.5×
calls. Depth is downsampled randomly from 30×. INDEL: insertion/deletion. SNV: single nucleotide variant. Boxes represent the interquartile range. Bold
horizontal lines in boxplots represent the median, the whiskers extend to 1.5 times the interquartile range, and grey dots represent outliers outside the
whisker range
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Reﬁnement of parameters for rare variant burden testing. We
carried out genome-wide rare variant burden analyses for six
medically-relevant traits: serum adiponectin, bilirubin, gamma-
glutamyltransferase, low- and high-density lipoprotein, and tri-
glyceride levels. As choice of genomic region, variant selection
and weighting remain open questions for rare variant analysis, we
benchmark 10 approaches using different regions of interest
(exonic, exonic and regulatory, and regulatory only), variant
inclusion and weighting methods (Methods; Supplementary
Table 1). Overall, association statistics correlate highly within
three distinct clusters (Supplementary Fig. 7). Among exonic-only
analyses, rare variant tests that only include unweighted high-
consequence variants cluster separately from those in which
variants are weighted according to their functionality scores. The
third cluster encompasses all tests that include regulatory var-
iants. Neither the variant weighting scheme nor the transforma-
tion used for adjusting the weights has a notable inﬂuence on the
results.
Rare variant burden discovery. In total, twenty burden signals
exceed the study-wide signiﬁcance threshold of 2.0 × 10−7 (Sup-
plementary Fig. 8), arising from four independent genes. Pro-
viding proof-of-principle, we identify association of a burden of
loss-of-function variants with blood triglyceride and high-density
lipoprotein levels in the APOC3 gene (Fig. 3.a, Supplementary
Data File 1)5,13. The strongest signal arises when the splice-donor
variant rs138326449 (minor allele count (MAC)= 38, minor
allele frequency (MAF)= 0.013) and the stop-gained variant
rs76353203 (MAC= 62, MAF= 0.022) are included in the ana-
lysis (P= 1.6 × 10−26). We replicate the association of a burden of
rare coding APOC3 variants with triglyceride levels in INTER-
VAL, in which we identify a burden of 25 exonic variants (P=
3.1 × 10−6) (Supplementary Data File 2). This is driven by
rs138326449 and rs187628630, a rare 3’ UTR variant (MAF=
0.008), with a two-variant burden P= 9.0 × 10−7. rs138326449 is
the only loss-of-function variant in APOC3 present in this cohort,
and is four times rarer than in MANOLIS (MAFINTERVAL= 0.003
vs MAFMANOLIS= 0.013).
We detect a new association of triglyceride levels with rare
variants in the FAM189B gene (Fig. 3.b, Supplementary Data
File 1). The burden association (P= 1.5 × 10−7) is driven by
two independent novel splice variants: chr1:155251911 G/A
(human genome build 38, MAC= 3, P= 8.2 × 10−6) and
chr1:155254079 C/G (MAC= 2, P= 6.04 × 10−4). In both cases,
the minor allele is associated with increased triglyceride levels
(effect size β= 2.59 units of standard deviation, σ= 0.57 and β=
2.40 σ= 0.69, respectively). Both variants exhibit high quality
scores (VQSLOD > 19), high sequencing read depth (24× and
26.5×, respectively) and no missingness. A further novel splice
region variant (chr1:155251496 T/C) and a stop gained variant
(rs145265828), both singletons, were also included in the analysis;
however their contribution to the burden is insigniﬁcant (burden
P= 2.2 × 10−8 when excluding them). We replicate evidence for a
burden signal at FAM189B in the INTERVAL cohort (P= 9.3 ×
10−3) (Supplementary Data File 2), which includes two stop
gained variants with one driving the association: chr1:155250417
(rs749626426, MAC= 2, β= 1.96 σ= 0.70, P= 5.4 × 10−3). In
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Fig. 2 Variant count proportions and minor allele frequency bin by functional class. a, b Data is shown for MANOLIS (a) and INTERVAL (b). Functional
classes are derived from the Ensembl VEP consequences as detailed in Supplementary Table 6. The number of intergenic variants is likely to be an
underestimate due to Ensembl’s most severe consequence annotation. For each panel, the bottom half represents the proportion of variants in each
class relative to the total number of variants, the upper half represents the frequency makeup of variants in each class
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keeping with the discovery dataset, the disruptive minor allele is
associated with increased triglyceride levels. The two novel splice-
region variants discovered in MANOLIS are not present in either
the INTERVAL study or in a compendium of 123,136 exomes
and 15,496 whole genomes assembled as part of the gnomAD
project11. FAM189B has not been previously associated with
blood lipid levels.
We ﬁnd evidence of a low frequency and rare variant burden
association with bilirubin levels in the UGT1A9 gene (Fig. 3.c,
Supplementary Data File 1). This association arises from the
analyses including exonic and regulatory variants (P= 1.9 × 10−8),
and from the analyses including regulatory variants only (P=
7.2 × 10−8). We ﬁnd evidence for association in the exon plus
regulatory region burden analysis in the INTERVAL replication
cohort (P= 1.7 × 10−45, Supplementary Data File 2). A common
variant in the ﬁrst intron of UGT1A9 (rs887829, MAF= 0.28, β=
0.426 σ= 0.04, two-sided score test P= 4.0 × 10−21 in the
MANOLIS cohort) has previously been associated with bilirubin
levels14,15. As expected, genotype correlation between rs887829
and each of the low-frequency and rare variants included in the
burden is low (rmax2= 0.1). The rs887829 signal is not attenuated
when conditioning on carrier status for the two main drivers of the
burden (single-point score test Pconditional= 4.5 × 10−21), or when
conditioning on the number of rare alleles carried per individual
(Pconditional= 4.0 × 10−21). The evidence for association with the
rare variant burden in UGT1A9 is substantially reduced when
conditioned on rs887829 (burden Pconditional= 0.0146). Conversely,
the two-variant signal for the two main burden drivers is
attenuated from P= 1.4 × 10−7 to Pconditional= 7.0 × 10−3 when
conditioning on rs887829, indicating that it likely recapitulates part
of a signal driven by a known common-variant association in the
region.
We identify an association of adiponectin levels with low-
frequency and rare variants in the ADIPOQ gene (Fig. 3.d,
Supplementary Data File 1). The evidence for association is
stronger for exonic and regulatory variants combined (P= 4.2 ×
10−8) than in either the regulatory-only (P= 0.19) or exon-only
(P= 2.0 × 10−6) analyses, suggesting a genuine contribution of
both classes of variants to the burden. The missense variant
rs62625753 (MAF= 0.031, two-sided score test P= 4.0 × 10−5)
contributes to the burden signal and is predicted to be damaging.
The strength of association for the burden is reduced, but not
entirely attenuated, when conditioned on rs62625753 (Pconditional
= 8.9 × 10−4), indicating that it is not singly driven by this
variant. rs35469083 (MAF= 0.044) also contributes to the
burden, and is an expression quantitative trait locus (eQTL) for
ADIPOQ in visceral adipose tissue (minor allele associated with
decreased gene expression). rs62625753 and rs35469083 have
116825000 116835000
Chromosome 11
0
2
4
6
8
10
12
14
16
18
20
22
24
26
a b c
ed
APOC3
−
Lo
g 1
0(p
)
155240000 155250000 155260000
0
2
4
6
FAM189B
Chromosome 1
233600000 233650000 233700000 233750000 233800000 233850000
0
2
4
6
8
10
12
14
16
18
20
UGT1A9
rs887829
Chromosome 2
0.1
0.39
0.68
0.97
1.26
1.56
1.85
2.14
186800000 186820000 186840000 186860000 186880000 186900000
0
2
4
6
8
−
Lo
g 1
0(p
)
ADIPOQ
rs62625753
rs35469083
0.22
0.52
0.82
1.12
1.41
1.71
2.01
2.31
Chromosome 3
24550000 24600000 24650000 24700000
0
2
4
6
GGT1
rs3859862
0
3.4
6.8
10.2
13.6
17
20.4
23.8
Chromosome 22
Fig. 3 Regional association plots for burdens in APOC3, FAM189B, UGT1A9, ADIPOQ, and GGT1. Red lines denote the burden P-value and extend over
the tested gene. Purple lines indicate the conditioned P-value for the variant described in the text (variants rs887829, rs62625753, and rs3859862 in
c, d, e. respectively). Small grey dots indicate single-point P-value for variants in the region not included in the test. Larger coloured dots represent variants
included in the test, with size and colour proportional to the score used in the most signiﬁcant test (Supplementary Table 1 and Supplementary Data File 1).
When no weights are applied (a and b), included variants are coloured blue-green. In the gene track below the regional plots, green bars below the gene, if
present, denote regulatory regions associated with the gene which were used to include variants in the burden. These are present only for genes where
regulatory regions were included in the burden
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consistent directions of effect, with the minor alleles associated
with reduced adiponectin levels, in keeping with their functional
consequences on the gene (two-variant burden P= 4.8 × 10−7).
No common-variant signal for adiponectin levels is present in
this region in our dataset. The burden signal remains signiﬁcant
upon conditioning on the genotypes of all variants with previous
associations for adiponectin, type 2 diabetes or obesity that are
polymorphic in MANOLIS (Supplementary Table 2).
In addition to the four genes that meet study-wide signiﬁcance,
we ﬁnd gamma-glutamyltransferase levels to be suggestively
associated with a burden of low frequency and rare exonic
variants in the gamma-glutamyltransferase 1 (GGT1) gene (P=
2.3 × 10−6) (Fig. 3.e, Supplementary Data File 1). A previously-
reported, common-variant association is also present in an intron
of this gene (rs3859862, MAF= 0.46, two-sided score test P=
1.9 × 10−6). The burden signal in GGT1 is maintained when
conditioning on rs3859862 (Pconditional= 5.1 × 10−5), suggesting
that rare variants be independently contributing to this established
association. Similarly, the single-point association at rs3859862
conditioned on carrier status for all rare variants included in the
burden is not attenuated (Pconditional= 2.8 × 10−5), a result
recapitulated by conditioning the same variant on the number
of rare alleles carried per individual (Pconditional= 1.8 × 10−5),
providing evidence for an independent rare variant signal at this
locus.
Signatures of selection. We surveyed the genomic loci with
evidence of rare variant burden signals for signatures of recent or
ongoing positive selection in the MANOLIS cohort, using inte-
grated haplotype scores (iHS)16. Previous studies have shown that
an elevated fraction of SNVs with |iHS| > 2 in a genomic region is
a signature of recent or ongoing selection and notably, we ﬁnd
that 32% of the SNVs in FAM189B have an iHS score above 2,
placing it in the top 5% of all genes analysed (96.7th percentile).
This result is robust across several deﬁnitions of the genomic
region representing the genes (95.6th-98.3th percentile) and to
conditioning on gene length (94.6th percentile) (Supplementary
Table 3). To further investigate this potential signature of selec-
tion in FAM189B, we examined the extent to which the allele
frequencies in FAM189B differ between the MANOLIS cohort
and the 1000 Genomes CEU population sample using weighted
mean FST. Like with iHS, FAM189B lies in the top 5% of all genes
analysed across several deﬁnitions of the genomic regions (Sup-
plementary Table 4).
Discussion
In this work, we have whole genome sequenced 1457 individuals
from the HELIC-MANOLIS cohort at an average depth of 22.5×.
We describe the genomic variation landscape in this special
population, discover 5.1 million novel variants, and perform rare
variant burden testing across the entire genome for medically-
relevant biochemical traits.
We empirically address several open whole genome sequencing
study design and analysis questions. Through a downsampling
approach, we demonstrate that it is possible to achieve near-
perfect sensitivity and quality for rare SNV calling and geno-
typing with half the depth, and at substantially lower cost,
compared to 30× sequencing. This observation does not extend to
INDELs, for which depth increases above 15× can result in a 15%
increase in genotype quality and a 40% increase in true positive
rate.
Deﬁning the genomic regions in which to select variants, ﬁl-
tering strategies and variant weighting schemes constitute unre-
solved challenges in whole genome sequence-based studies. We
ﬁnd that association signal proﬁles of tests including regulatory
region variants differ markedly from other scenarios, with some
signals being driven by this variant class. Further, signal strength
differs substantially between analyses that include high-severity
consequence exonic variants only, and those in which all exonic
variants are weighted according to their predicted consequence.
We ﬁnd that, as a rule, variant and functional unit selection,
rather than weighting scheme, plays the largest role in association
testing.
We identify a role for rare regulatory variants in the allelic
architecture of complex traits. It is therefore important to leverage
the whole genome sequence nature of the study data, and not to
restrict analyses to coding variation only. We observe congruent
directions of effect among regulatory and coding rare variants in
burden signals that combine both classes of variation, for example
across eQTL and damaging missense variants in the ADIPOQ
gene that are together associated with adiponectin levels.
We discover replicating evidence for association of a rare
variant burden with triglyceride levels at a locus not previously
linked with the trait. FAM189B (Family With Sequence Similarity
189 Member B), also known as COTE1 or C1orf2, codes for a
membrane protein that is widely expressed, including in adult
liver tissue17. Expression of FAM189B has been found to be
correlated with endogenous SREBP-1 activation in vitro18. Sterol-
regulatory element binding proteins (SREBPs) control the
expression of genes involved in fatty acid and cholesterol bio-
synthesis, therefore indicating a mechanism by which FAM189B
could be involved in lipid metabolism. We found FAM189B to
contain an elevated fraction of SNVs with |iHS|>2, a potential
signature of recent positive selection. Furthermore, FAM189B is
in the top 5% of all genes in terms of population differentiation
(FST) between the MANOLIS cohort and the 1000 Genomes
Project CEU sample, which is consistent with selection having
happened in MANOLIS. This is particularly interesting in the
context of this population, which has a high animal fat content
diet6, and for which loss of function variants in APOC3 have risen
in frequency compared to the general population and confer a
cardioprotective effect19,20. For the same reason, it is interesting
to note that FAM189B has not previously been reported to be
under selection in other populations21. However, we caution that
although FAM189B is in the top 5% of all genes for both iHS and
FST, it is not an extreme outlier for either, suggesting that it could
be a false positive or that the selection has not acted strongly
enough or for long enough to leave more than subtle signatures in
the haplotype structure and allele frequencies in the gene. It is
also possible that selection has acted on several rare alleles
making the signature more complex than simple directional
selection.
We replicate the FAM189B association in an independent
dataset with deep whole genome sequence data, in which the
disruptive rare alleles are also associated with the same trait in the
same direction. Across the board, we replicate all burden signals
for which replication cohort trait measurements are available. We
ﬁnd that allelic heterogeneity is prevalent, partly due to the rare
nature of the variants contributing to the burdens, and partly due
to the distinct population genetics characteristics of the discovery
and replication sets. Perhaps as a consequence, the outcome of
variant ﬁltering and weighting was quite sensitive to the study
population, and all the burdens reported here replicated strongest
in slightly different testing conditions from the discovery,
although in the same broad functional class. The association in
FAM189B was discovered when including exonic variants with a
relaxed severity threshold, whereas it replicated in the LoF-only
analysis. Similarly, the APOC3 signal was discovered in the LoF-
only analysis but replicated in the CADD-weighted exonic ana-
lysis. These ﬁndings have important consequences for deﬁning
replication in sequence-based studies of rare variants, and
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highlight the importance of deﬁning replication at the locus level
rather than the variant level for burden signals.
We demonstrate pervasive allelic heterogeneity at complex trait
loci, and identify exonic and regulatory rare variant associations
at established signals. We ﬁnd multiple instances of burden sig-
nals that remain independent of colocalising common variant
signals, and one instance of burden signal attenuation when
conditioning on the established common variant association.
Within the power constraints of the study, we do not ﬁnd evi-
dence for synthetic association at established signals, i.e., there is
no evidence for multiple rare variants at a locus accounting for a
common variant association.
The discovery of rare variant burden associations with a
modest sample size has been made possible due to the special
population genetics characteristics of the isolated cohort under
study. Rare variant signals, such as the ones discovered in APOC3
and FAM189B in MANOLIS, are driven by variants with severe
consequences that are rarer or absent in cosmopolitan popula-
tions. This demonstrates that the well-rehearsed power gains
conferred by isolated cohorts in genome-wide association studies3
extend to whole genome sequence-based rare variant association
designs.
Our ﬁndings indicate that deep whole genome sequencing at
scale will be required to enable exhaustive description of the rare
variant burden landscape in a population. For example, in the
case of the FAM189B signal, low-depth sequencing (1× depth) of
1239 MANOLIS samples22 misses one of the two burden-driving
variants (chr1:155251911, MAC= 3). Similarly, genome-wide
genotyping coupled to dense imputation of the same samples
does not capture the variants driving the burden signal identiﬁed
here through deep whole genome sequencing23.
Our ﬁndings provide evidence for a role of low-frequency and
rare, regulatory and coding variants in complex traits, and
highlight the complex nature of locus-speciﬁc architecture at
established and newly emerging signals. We anticipate that larger-
scale, cohort-wide, deep whole genome sequencing initiatives will
substantially further contribute to our understanding of the
genetic underpinning of complex traits.
Methods
Ethics and informed consent statement. In the TEENAGE study, prior to
recruitment all study participants gave their verbal assent along with their parents’/
guardians’ written consent forms. The study was approved by the Institutional
Review Board of Harokopio University and the Greek Ministry of Education,
Lifelong Learning and Religious Affairs. The MANOLIS study was approved by the
Harokopio University Bioethics Committee and informed consent was obtained
from every participant. The INTERVAL study was approved by the Cambridge
South Research Ethics Committee and informed consent was obtained from every
participant.
Sequencing. For MANOLIS, genomic DNA (500 ng) from 1482 samples was
sheared to a median insert size of 500 bp and subjected to standard Illumina
paired-end DNA library construction. Adapter-ligated libraries were ampliﬁed by 6
cycles of PCR and subjected to DNA sequencing using the HiSeqX platform
(Illumina) according to manufacturer’s instructions. For TEENAGE, one hundred
samples from the general Greek population were sequenced, as well as the Genome
in a Bottle NA12878 sample. Sample identity checks were performed using Flui-
digm and aliquots prepared. These aliquots underwent library preparation using
the standard HiSeqX method. Size selection was performed to target 350 base pairs.
Sequencing was performed on the Sanger Institute’s Illumina HiSeqX plat-form
with a target depth of 30x and PhiX spike-in.
Evaluation of sequencing accuracy at various depths. Reads from the NA12878
were downsampled to several read depths (from 5× to 30×) using the -s option of
samtools view, aligned and processed through GATK Variant Quality Score
Recalibrator. They were then compared to Genome in a Bottle (GIAB) 0.2 calls to
extract the true positive rate (Supplementary Fig. 2). At 22.5×, true positive rates
are 98% for SNVs and 76% for INDELs.
Comparison with the general Greek population. We compared variant callsets in
MANOLIS to a dataset of 100 samples from the Greek general population
(TEENAGE study), for which an identical sequencing protocol was used. The
average depth in the TEENAGE study was 32.1×. We downsampled the individual
BAMs to 22.5× and 15× using the -s option of samtools based on the average depth
of the TEENAGE dataset, then performed variant calling using GATK Haploty-
peCaller v3.3 (https://github.com/mp15/af_analysis) and ﬁltering using GATK
Variant Quality Score Recalibrator. The downsampled and original datasets were
then compared using bcftools stats to extract allelic r-squared (Fig. 1.b.). For the
22.5× dataset, we compared variant overlap with bcftools isec (Fig. 1.a. and Sup-
plementary Fig. 3).
Rare variant counts in MANOLIS, TEENAGE and INTERVAL. Since sample sizes
differ between the three datasets, we randomly subsampled the larger dataset to a
matching size for each pairwise comparison. We used these resampled datasets to
build empirical distributions for rare variant counts in the larger dataset, and
compared it to counts in the smaller dataset. TEENAGE (n= 100) was smaller
compared to MANOLIS (n= 1482), so we drew 1000 sets of 100 samples from the
MANOLIS study for the comparison. We counted 270,916 singletons and 61,690
doubletons in TEENAGE, compared with a median of 179,100 (one-sided P=
1.4 × 10−94 from a ﬁtted normal distribution) and 75,280 (one-sided P= 3.0 ×
10−19 from a ﬁtted normal distribution), respectively, in MANOLIS (Supple-
mentary Fig. 5a,b.). For n= 100, singletons correspond to MAF < 0.005 and dou-
bletons to 0.005 <MAF < 0.1.
For the INTERVAL (n= 3742) comparison, MANOLIS was the smaller dataset,
so we resampled 500 sets of 1482 samples from the INTERVAL cohort and
counted variants up to MAC= 29 (MAF= 0.01). The increased resolution
provided by this larger sample size shows that rare variant counts are greater in the
cosmopolitan population below MAC= 4 (MAF= 0.0013), but greater in the
isolate for 0.0013 <MAF < 0.1, consistent with our coarser observation in
TEENAGE (Supplementary Fig. 5.c).
For p-values of singleton counts, empirical quantiles cannot be computed for
such large deviations from the mean. We ﬁtted a normal distribution to singleton
counts, and computed the theoretical quantile corresponding to the observed count
in the smaller cohort.
Variant calling. Basecall ﬁles for each lane were transformed into unmapped
BAMs using Illumina2BAM, marking adaptor contamination and decoding bar-
codes for removal into BAM tags. PhiX control reads were mapped using BWA
Backtrack and were used to remove spatial artefacts. Reads were converted to
FASTQ and aligned using BWA MEM 0.7.8 to the 1000 Genomes hs37d5 (for
NA12878) and hg38 (GRCh38) with decoys (HS38DH) (for TEENAGE) refer-
ences. The alignment was then merged into the master sample BAM ﬁle using
Illumina2BAM MergeAlign. PCR and optical duplicates are marked using bio-
bambam markduplicates and the ﬁles were archived in CRAM format.
Per-lane CRAMs were retrieved and reads pooled on a per-sample basis across
all lanes to produce library CRAMs; these were each divided in 200 chunks for
parallelism. GVCFs were generated using HaplotypeCaller v.3.5 from the Genome
Analysis Toolkit (GATK) for each chunk. All chunks were then merged at sample
level, samples were then further combined in batches of 150 samples using GATK
CombineGVCFs v.3.5. Variant calling was then performed on each batch using
GATK GenotypeGVCFs v.3.5. The resulting variant callsets were then merged
across all batches into a cohort-wide VCF ﬁle using bcftools concat.
Quality control. Variant-level QC was performed using the Variant Quality Score
Recalibration tool (VQSR) from the Genome Analysis Toolkit (GATK) v. 3.5-0-
g36282e424, using a tranche threshold of 99.4% for SNPs, which provided an
estimate false positive rate of 6%, and a true positive rate of 95%. For INDELs, we
used the recommended threshold of 1%. For sample-level QC, we made extensive
use of a previously described23 GWAS dataset in 1175 overlapping samples. Four
individuals failed sex checks, 8 samples had low concordance (π^<0:8) with chip
data, 11 samples were duplicates, and 12 samples displayed traces of contamination
(Freemix score from the verifyBamID suite25>5%). In case of sample duplicates, the
sample with highest quality metrics (depth, freemix and chipmix score) was kept.
As contamination and sex mismatches were correlated, a total of 25 individuals
were excluded (n= 1457). No further samples were excluded based on depth,
heterozygosity, transition/transversion (Ti/Tv) rate, missingness or ethnicity. No
rare or low-frequency variant (MAF < 5%) was excluded based on the Hardy-
Weinberg equilibrium test at P= 1.0 × 10−5. We ﬁltered out 14% of variants with
call rates < 99%.
Genetic relatedness matrix. Several methods are available to estimate the genetic
relatedness present in isolated cohorts such as HELIC-MANOLIS26. We compared
methods proposed in GEMMA27, EMMAX28, KING29 and PLINK30., and found
that the kinship coefﬁcients reported by each method were highly correlated, but
on a different scale from each other (Supplementary Fig. 9). For consistency with
previous studies performed on the same samples, we calculated a genetic related-
ness matrix using GEMMA27 after ﬁltering for MAF < 0.05, missingness <1% and
LD-based pruning. In addition, MONSTER requires self-kinship coefﬁcients on the
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diagonal of the relatedness matrix, which we calculated using the bF1 metric from
PLINK 1.9. The matrix was then converted to the long format using the reshape2 R
package.
Association testing. Burden testing was performed using MONSTER31, a method
that extends the SKAT-O32 model to account for relatedness and/or structure
present in cohorts such as population isolates when testing for association. We ran
burden testing across all genes deﬁned in GENCODE v25 using 10 different
conditions, i.e., combinations of regions of interest (coding regions only, coding
and regulatory regions and regulatory regions only), variant ﬁlters (inclusion cri-
teria based on severity of predicted consequence) and weighting schemes (Sup-
plementary Table 1). QQ-plots for all testing conditions and traits are presented in
Supplementary Fig. 10.
First, we extracted exonic coordinates for all protein-coding genes, which
deﬁnes the region of interest for strictly exonic variants. These regions of interest
were used in combination with 5 different variant ﬁltering and weighting schemes.
First, we included only variants predicted as high-conﬁdence (HC) loss-of-function
(LoF) by LOFTEE8 that reside in the exons of protein-coding genes
(Supplementary Table 1: LOFTEE HC). As only 460 variants in 85 genes passed
this inclusion criterion, we performed an additional analysis including 8,570 low-
conﬁdence (LC) loss-of-function variants spread across 1,727 genes
(Supplementary Table 1: LOFTEE LC). Stop-gained and frameshift mutations were
the largest contributors to both the LC and HC sets. However, the LC set also
includes a large number of splice donor and splice acceptor variants
(Supplementary Fig. 4). We further performed an analysis with more relaxed
inclusion criteria, including all exonic variants for which the Ensembl most severe
consequence was more damaging than missense as predicted by the Variant Effect
Predictor33 (Supplementary Table 1: Exon severe). We also employed Combined
Annotation Dependent Depletion (CADD)34 scores, either to weigh all exonic
variants (Supplementary Table 1: Exon CADD) or to ﬁlter out variants with CADD
scores below the genome-wide median (Supplementary Table 1: Exon CADD
median). Finally, we extended exon boundaries as deﬁned above with 50 base pairs
either side, to account for cases where potentially damaging variants occur on the
edges of exons, as has been shown to happen for previously identiﬁed rare variant
burdens5. These regions of interest were used in combination with one variant
weighting scheme only (Exon+ 50 CADD).
We extracted regulatory regions (promoters, enhancers and transcription-factor
binding sites) from Ensembl build 8412. We assigned regulatory regions to genes if
they directly overlapped or if the regulatory region overlapped with an eQTL for
the gene based on the GTEx database35. If an eQTL was reported for several genes,
overlapping variants were assigned to all of them. We did not take tissue speciﬁcity
into account. For selecting variants, we either used the coordinates of the regulatory
features alone, or regulatory features plus the extended exons. We used Eigen, an
aggregate score that combines information from multiple regulatory annotation
tracks36, to weigh variants in all tests that include regulatory variants. In addition
to raw Eigen scores, the authors also proposed EigenPC, a score derived from the
ﬁrst eigenvector of the correlation matrix of annotations. Both scores were available
as is, or transformed using Phred-scaling, which maps a distribution’s support
to] 0,+∞[, thereby guaranteeing inclusion and relative up-weighting of all variants.
In the regulatory regions plus exon analyses we used both the raw Eigen scores,
shifted by 1 unit to the right, with negative scores set to 0þ ϵ (Supplementary
Table 1: Exon and regulatory Eigen), and the Phred-transformed Eigen and
EigenPC scores (Supplementary Table 1: Exon and regulatory EigenPhred and
EigenPCPhred). This transformation was a technical requirement as MONSTER
could only read weights belonging to ]0,+∞[. In the analyses containing the
regulatory regions only, variants were weighted using the Phred-scaled Eigen scores
(Supplementary Table 1: regulatory only EigenPhred) only.
Finally, we applied a MAF threshold of 0.05, a missingness threshold of 1% and
a Hardy–Weinberg ﬁlter using a mid-p adjusted P-value37 threshold of 1.0 × 10−5
to all variants prior to testing. We only performed a test if at least two SNVs passed
the inclusion criteria for a given condition.
Establishing the signiﬁcance threshold. We calculated αeff ¼ 0:05N ´ ncond ´M ;where N
is the number of genes tested, ncond is the effective number of inclusion and
weighting criteria tested and M=6 is the number of traits. For ncond, we plotted the
correlation matrix of z-scores for all 10 analyses, and determined that the analyses
using similar region deﬁnitions (exonic loss-of-function, exonic, exonic and reg-
ulatory variants) cluster together, reducing the effective number of analyses to 3
(Supplementary Fig. 7). Although N= 18,997 protein-coding genes are available in
GENCODE V25, not all genes were tested in every condition. For example, for
many genes only one variant might pass inclusion criteria in a high-conﬁdence
loss-of-function run, thereby excluding those genes from the analysis. A summary
of the number of genes included in every analysis is presented in Supplementary
Table 5. On average, N= 13,854 genes are included, hence we deﬁne study-wide
signiﬁcance at P= 2.0 × 10−7.
Burden prioritisation and novelty. We applied stringent checks to test the validity
of rare variant burden association signals. Every suggestively associated burden
(arbitrarily deﬁned as P ≤ 5 × 10−5) was conditioned on the genotypes of the
variant included in the burden set with the lowest single-point P-value. If the P-
value dropped more than two orders of magnitude below the suggestive sig-
niﬁcance threshold (i.e., P ≤ 5.0 × 10−3), the burden was excluded from down-
stream analyses. We examined burden signals using the plotburden software
(https://github.com/wtsi-team144/plotburden) to assess variant functionality,
single-point association P-values, LD structure, as well as prior associations in the
region. When a prior association was found in the region, we considered a signal
known when the P-value dropped below P= 1.0 × 10−4 when conditioning on the
genotypes of the existing signal. We examined rare variant burden associations
with suggestive signiﬁcance (P < 5 × 10−5) across the six traits under investigation,
and do not ﬁnd evidence of further rare variant signals at established loci.
Replication. The INTERVAL randomised controlled trial is a large-scale study
focusing on healthy blood donors10. Sequencing, variant calling and quality control
was performed for 3762 INTERVAL participants using the same protocol and
pipeline as for the MANOLIS sequences. 38 samples were excluded on the basis of
ethnicity, excessive relatedness (π^ > 0.125), excess heterozygosity and contamina-
tion. VQSR thresholds of 99 and 90% for SNVs and INDELs, respectively, were
applied to variant calls. Gamma-glutamyltransferase and adiponectin levels were
not available in the INTERVAL replication cohort.
Selection analyses. For the selection analyses we used the haplotype-based iHS
statistic16. We used this statistic because we were mainly interested in recent or
ongoing selection, i.e., selective sweeps where the advantageous allele has not yet
reached a high frequency (>80%), and iHS has been shown to be more powerful
than other commonly used statistics like Tajima’s D38 and XP-EHH39 for detecting
such sweeps16,40. Brieﬂy, the iHS value of an SNV becomes elevated when one of
the alleles of that SNV reside on haplotypes that are longer than expected under
neutrality, given the frequency of the allele. This is considered a signature of
positive selection because positive selection will cause haplotypes carrying an
advantageous allele to increase in frequency faster than if the allele had been
neutral which leaves less time for recombination to shorten them.
To investigate if any of the four genes with study-wide signiﬁcant burden
association signals have undergone recent or ongoing positive selection, we
calculated the fraction of SNVs with |iHS|>2 for these four genes and assessed if
these fractions were elevated by comparing them to the empirical distribution for
all genes. We focused on the fraction of SNVs with |iHS|>2, because previous
studies have compared different methods of summarising iHS for a genomic region
of interest, and found that the fraction of SNVs |iHS|>2 is often the most powerful
iHS summary for detecting selection16,40.
The primary data used for the selection analyses is the MANOLIS genotype data
described above, which we phased using Beagle v.4.141. We also used the ancestral
allele annotations for each site in hg38 from ENSEMBL, and the recombination
map from UCSC, which was built on hg37 and lifted-over to hg38. From this map,
we excluded 3140 sites to achieve a recombination map with monotonically
increasing cM positions. Linear interpolation was subsequently used to produce cM
positions for all sites not found on the map. For quality control, we combined the
MANOLIS genotype data with genotype data from the 1000 Genomes phase 342.
Because close relatives can complicate and potentially bias analyses of signals of
selection, we removed close relatives within the MANOLIS data after phasing, as
well as one admixed individual. We used the same criteria as in a previous study of
this population4, i.e., we used the --genome option in PLINK 1.9 to estimate PI-
HAT and randomly excluded one individual from each pair of individuals with
π^>0.2. These exclusions left 810 unrelated individuals from MANOLIS, on which
we based the selection analysis.
We restricted our iHS analysis to known, common SNVs with ancestral allele
annotations. Speciﬁcally, we excluded sites: not on the autosomes, with more than
2 alleles, with alleles that were not length 1 (INDEL-like), with MAF < 0.05, without
ancestral allele annotations, with HWE midp-value < 1 × 10−30, not present in 1000
Genomes phase 3 vcf ﬁles, or that were outside a mappable region of the hg38
reference genome, deﬁned as a GEM 100-mer score below 0.843. These ﬁltering
steps resulted in 5,126,987 SNVs as input for iHS calculations.
The iHS statistic was calculated with the hapbin program44, using default
parameters. The raw iHS statistic is sensitive to allele frequency, so SNVs were
subsequently binned by derived allele count (82 equally-spaced bins) and the iHS
statistic was normalised within each bin to have a mean of zero and a standard
deviation of one, as suggested in16. Finally, we examine the absolute value of the
normalised iHS statistic to capture selection signals associated with both derived
and ancestral alleles. Due to edge effects at chromosome ends and other gaps, we
examine iHS values for 5,116,861 SNVs (99.8% of input sites).
For each gene, we considered four distinct ways to deﬁne the genomic region
representing the gene: (1) sites within exons, (2) sites within exons extended by
50 bp or in regulatory elements, (3) sites within the region spanned by connecting
all exons, and (4) sites within the region spanned by connecting all exons extended
by 50 bp and regulatory elements. For each gene and each of the four genic region
deﬁnitions, we extracted SNVs with an iHS value and calculated the fraction of
SNVs with normalised |iHS| above 2. When interpreting our results, we mainly
focused on the results for the most inclusive deﬁnition, deﬁnition 4, as selection
signatures tend to span fairly large genomic regions, but included the other
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deﬁnitions to be able to assess if this choice of deﬁnition markedly affected our
results.
For each lead gene with a rare variant study-wide signiﬁcant burden signal
(APOC3, UGT1A9, ADIPOQ, and FAM189B), we compared its fraction of SNVs
with |iHS|>2 to all other genes with at least 1 iHS value-bearing SNV, using each of
the four different gene region deﬁnitions. Each comparison was quantiﬁed by the
percentile of genes with a higher fraction of SNVs with |iHS|>2. FAM189B was the
only of the four burden genes with a fraction |iHS|>2 above zero. For this gene, we
also performed a comparison to the subset of genes with a similar number of SNVs
with iHS values as FAM189B (deﬁned as +/− 10% of the number of SNVs with
iHS in FAM189B) to ensure the varying number of SNVs in the genes we compared
FAM189B to did not drastically affect the percentiles. Note that with the gene
deﬁnitions used some SNVs will be included in several genes and thus the data
points in the empirical distribution used for comparison are not entirely
independent.
FST between two populations is a measure of population differentiation and is
expected to increase in a region harbouring an allele which has been under positive
selection mainly in one of the two populations.
To further investigate the FAM189B gene we calculated FST between the
MANOLIS cohort and the European 1000 genomes CEU population for this gene
and compared it to that of all other genes. The comparison was performed like for
the iHS values, i.e., using quantiles and by performing several different
comparisons to check for robustness of the results. For this analysis, we used the
same genetic data from MANOLIS as for the iHS analyses combined with data
from the 1000 genomes CEU population sample, except we did not ﬁlter away
SNVs with MAF < 0.05, without ancestral allele annotations or with HWE midp-
value < 1 × 10−30. Following published recommendations45, all FST estimates were
performed using the Hudson estimator and per SNP estimates were combined
using the ratio of the average numerator and the average denominator (also
referred to as weighted mean FST). However, we note that similar results were
obtained using the Weir and Cockerham FST estimator46.
Code availability. MUMMY, the script used to run burden tests genome wide
using MONSTER, is available at https://github.com/wtsi-team144/burden_testing.
The plotburden script, which builds interactive visualisations of burden signals, is
available at https://github.com/wtsi-team144/plotburden.
Data availability
Sequencing data are available at the European Genome-Phenome Archive under
accession numbers EGAS00001001207 for MANOLIS, EGAS00001000988 for
TEENAGE, and EGAS00001001355, EGAS00001002461, and EGAS00001002787
for INTERVAL.
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